£195.00
For research use only — Not for human or animal use
Retatrutide 40mg Pen is a triple receptor agonist studied for its role in metabolism, appetite regulation, and body weight management. Developed by Eli Lilly, it has become one of the most closely watched compounds in clinical research because it targets three separate hormone pathways involved in energy balance and metabolic function.
Unlike traditional weight loss treatments that focus on a single pathway, Retatrutide works as an agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Researchers are particularly interested in how this combined approach may influence appetite, energy expenditure, and metabolic adaptation over longer observation periods.
Its unique mechanism has led to comparisons with newer metabolic therapies currently being studied for obesity and type 2 diabetes. Ongoing phase 3 clinical trials continue to evaluate its long-term effects and safety profile.
Retatrutide is a synthetic peptide designed to activate three hormone receptors associated with metabolism and weight regulation:
This combination of GLP-1, GIP and glucagon receptors has made Retatrutide unique within metabolic research, as scientists continue exploring how these pathways may work together to influence body weight and metabolic health.
Interest in Retatrutide accelerated following the publication of clinical research showing significant changes in body weight and metabolic markers.
In a 48-week Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest weekly dose achieved an average body weight reduction of up to 24.2%. Researchers also reported improvements in metabolic measures linked to obesity and glucose regulation.
One of the most notable findings was that weight reduction was still continuing when the study ended, suggesting the full effect may not have been reached during the observation period.
Current areas of research include:
Several phase 3 clinical trials are currently underway to further evaluate efficacy, safety, and long-term outcomes across larger populations.
Many existing weight-loss treatments work through a single receptor pathway. Retatrutide differs because it combines glucagon-like peptide-1 GLP-1 activity with glucose-dependent insulinotropic polypeptide GIP and glucagon receptor activation.
Researchers believe this broader approach may influence both energy intake and energy expenditure, which is one reason it has generated significant attention within obesity and metabolic research.
Because of these findings, Retatrutide is frequently discussed alongside other next-generation metabolic therapies currently being evaluated through clinical research programmes.
Research involving Retatrutide has explored several areas related to metabolism, appetite regulation, and body weight management.
Published studies have investigated:
Researchers are particularly interested in how combining GLP-1, GIP, and glucagon receptor activity may influence broader metabolic systems compared with single-pathway compounds.
As with similar compounds, side effects continue to be evaluated throughout ongoing studies. The most commonly reported observations have included nausea, vomiting, diarrhoea and other gastrointestinal effects, particularly during dose-escalation periods. These events were generally reported as mild to moderate in severity.
Our Retatrutide 40mg Pen is supplied in a pre-filled pen format designed for controlled handling and storage.
Standard handling practices include:
Disclaimer: This product is sold strictly for research purposes only. Not for human consumption.
Discount Applied Successfully!
Your savings have been added to the cart.
